Talk:EMPA-REG OUTCOME
Jump to navigation
Jump to search
Statements from the "criticisms" and "funding" may need to be exchanged.
- Interesting thought, we have tried to keep criticisms about funding mechanisms in the funding section for simplicity's sake. The exceptions to this would be an egregious conflict of interest, like in the Vioxx VIGOR trial[1] and exclusion of endpoints. There are concerns that authors from Merck opted not to include MIs, in this instance.[2] --Tim Plante (talk) 11:12, 13 April 2016 (UTC)